We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$44.5B
AUM Growth
-$1.18B
(-2.6%)
Cap. Flow
-$4.15B
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
9.83%
Holding
3,927
New
652
Increased
690
Reduced
847
Closed
1,056
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$309M |
| 2 |
ExxonMobil
XOM
|
+$302M |
| 3 |
Amazon
AMZN
|
+$291M |
| 4 |
Citigroup
C
|
+$253M |
| 5 |
Shopify
SHOP
|
+$238M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$383M |
| 2 |
Johnson & Johnson
JNJ
|
+$312M |
| 3 |
JPMorgan Chase
JPM
|
+$285M |
| 4 |
AT&T
T
|
+$191M |
| 5 |
Dollar General
DG
|
+$187M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.63% |
| 2 | Financials | 15.61% |
| 3 | Technology | 14.28% |
| 4 | Consumer Discretionary | 13.21% |
| 5 | Industrials | 5.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Thermo Fisher Scientific
TMO
$211B
| $221M | 0.5% |
400,574
-62,242
| -13% | -$33M |
|
27
Crocs
CROX
$6.69B
| $220M | 0.49% |
2,027,332
+309,704
| +18% | +$27.4M |
|
28
Newmont
NEM
$98.2B
| $220M | 0.49% |
4,653,920
+2,165,084
| +87% | +$96.7M |
|
29
US Bancorp
USB
$99.6B
| $219M | 0.49% |
5,023,389
+3,170,503
| +171% | +$136M |
|
30
Agilent Technologies
A
$39.1B
| $215M | 0.48% |
1,436,942
-185,569
| -11% | -$26.5M |
|
31
CALL
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$16.3B
| $214M | 0.48% |
2,908,200
-1,006,100
| -26% | -$74.2M |
|
32
Danaher
DHR
$135B
| $211M | 0.48% |
898,676
+801,538
| +825% | +$186M |
|
33
McDonald's
MCD
$188B
| $207M | 0.47% |
787,261
+439,379
| +126% | +$116M |
|
34
Enphase Energy
ENPH
$4.84B
| $206M | 0.46% |
775,809
+164,865
| +27% | +$48M |
|
35
Qualcomm
QCOM
$176B
| $204M | 0.46% |
1,852,485
-84,032
| -4% | -$9.83M |
|
36
CALL
iShares Russell 2000 ETF
IWM
$80.9B
| $203M | 0.46% |
1,165,300
+840,800
| +259% | +$150M |
|
|
37
JPMorgan Chase
JPM
$939B
| $195M | 0.44% |
1,452,223
-2,247,728
| -61% | -$285M |
|
38
Charles River Laboratories
CRL
$10.9B
| $191M | 0.43% |
874,773
+319,095
| +57% | +$69.7M |
|
39
Elevance Health
ELV
$81.9B
| $188M | 0.42% |
+366,649
| New | +$186M |
|
40
American International
AIG
$41.9B
| $187M | 0.42% |
2,963,318
-2,004,208
| -40% | -$117M |
|
41
Pinterest
PINS
$12.4B
| $187M | 0.42% |
7,700,136
-2,582,266
| -25% | -$61.6M |
|
42
Bilibili
BILI
$7.18B
| $180M | 0.4% |
7,588,102
+4,536,242
| +149% | +$72.2M |
|
43
Annaly Capital Management
NLY
$16.9B
| $177M | 0.4% |
8,376,819
-976,200
| -10% | -$19.2M |
|
44
Alphabet (Google) Class A
GOOGL
$3.91T
| $173M | 0.39% |
1,955,626
-124,301
| -6% | -$11.8M |
|
45
Intel
INTC
$466B
| $172M | 0.39% |
6,523,063
-2,916,642
| -31% | -$81M |
|
46
S&P Global
SPGI
$126B
| $171M | 0.38% |
510,667
+305,362
| +149% | +$101M |
|
|
VMW
47
DELISTED
VMware, Inc
VMW
| $167M | 0.38% |
1,363,167
-1,353,369
| -50% | -$156M |
|
|
SKX
48
DELISTED
Skechers
SKX
| $167M | 0.38% |
3,987,863
-103,415
| -3% | -$3.96M |
|
49
Paychex
PAYX
$40.4B
| $166M | 0.37% |
1,437,729
+699,825
| +95% | +$81.9M |
|
50
PepsiCo
PEP
$186B
| $161M | 0.36% |
891,989
+364,971
| +69% | +$65.1M |
|
Similar funds
Marshall Wace's Q4 2022 Portfolio in Review
As of Q4 2022, Marshall Wace held 3,927 positions worth $44.5B, down 2.6% from $45.6B the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
Marshall Wace withdrew a net $4.15B in Q4 2022, closing 1,056 positions and reducing 847 holdings. Its most notable exit was Humana, an estimated $383M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Financials and Technology.
Against the trend, Marshall Wace opened a new position in Elevance Health worth $188M.
- Marshall Wace's largest Q4 2022 buy was Elevance Health: 366,649 shares worth $188M.
- Marshall Wace added most to Biogen in Q4 2022, an estimated $309M increase.
- Marshall Wace's biggest Q4 2022 reduction was Johnson & Johnson, cutting an estimated $312M.
- Marshall Wace fully exited Humana in Q4 2022, selling an estimated $383M.
- Marshall Wace's ten largest holdings make up 9.8% of its $44.5B portfolio in Q4 2022.
- Marshall Wace opened 652 new positions and closed 1,056 in Q4 2022.
- Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $44.5B.
Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.